![](/images/graphics-bg.png)
Preclinical Evidence of Curcuma longa and Its Noncurcuminoid Constituents against Hepatobiliary Diseases: A Review
Joint Authors
Lee, Jang-Hoon
Jang, Eungyeong
An, Soyeon
Source
Evidence-Based Complementary and Alternative Medicine
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-07-29
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
Hepatobiliary disease currently serves as an important public health issue due to the fact that it is one of the major causes of death among economically active individuals and can easily progress to chronic diseases.
Despite the development of vaccines and numerous drugs, a definite treatment remains lacking owing to different stages of the disease itself, its intricate pathogenesis, an effect uncertainty for long-term use, resistance, and side effects.
Curcuma longa (C.
longa), which belongs to the family Zingiberaceae and the genus Curcuma, has long been used not only as spice for curry or dye but also as a constituent of herbal formula for the treatment of different diseases due to its bioactive activities.
Recently, many studies on the experimental results of C.
longa have been published relative to hepatobiliary diseases such as fatty liver, hepatitis, cirrhosis, and tumors.
Therefore, in this review, we aimed to summarize the pharmacological effects and underlying molecular mechanisms of C.
longa and its four compounds, β-elemene, germacrone, ar-turmerone, and bisacurone, against hepatobiliary diseases.
C.
longa exhibited antioxidant, hepatoprotective, antisteatotic, anti-inflammatory, antifibrotic, antitumor, and cholagogic effects by regulating apoptosis, CYP2E1, Nrf, lipid metabolism-related factors, TGF-β, NF-κB, CYP7A1, and so on.
In particular, β-elemene could be an attractive compound owing to its remarkable hepatoprotective, anti-inflammatory, antifibrotic, and antitumor activities.
Altogether, the present review provides a preclinical basis for the efficacy of C.
longa as an effective therapeutic agent for the prevention and treatment of hepatobiliary diseases, despite the need for further studies to establish the extraction conditions and separation of active constituents with high bioavailability, and warrants further evaluation in clinical trials.
American Psychological Association (APA)
An, Soyeon& Jang, Eungyeong& Lee, Jang-Hoon. 2020. Preclinical Evidence of Curcuma longa and Its Noncurcuminoid Constituents against Hepatobiliary Diseases: A Review. Evidence-Based Complementary and Alternative Medicine،Vol. 2020, no. 2020, pp.1-11.
https://search.emarefa.net/detail/BIM-1157922
Modern Language Association (MLA)
An, Soyeon…[et al.]. Preclinical Evidence of Curcuma longa and Its Noncurcuminoid Constituents against Hepatobiliary Diseases: A Review. Evidence-Based Complementary and Alternative Medicine No. 2020 (2020), pp.1-11.
https://search.emarefa.net/detail/BIM-1157922
American Medical Association (AMA)
An, Soyeon& Jang, Eungyeong& Lee, Jang-Hoon. Preclinical Evidence of Curcuma longa and Its Noncurcuminoid Constituents against Hepatobiliary Diseases: A Review. Evidence-Based Complementary and Alternative Medicine. 2020. Vol. 2020, no. 2020, pp.1-11.
https://search.emarefa.net/detail/BIM-1157922
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1157922